Načítá se...
Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series
BACKGROUND: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free...
Uloženo v:
| Vydáno v: | Ecancermedicalscience |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Cancer Intelligence
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6214673/ https://ncbi.nlm.nih.gov/pubmed/30483355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2018.875 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|